ClinicalTrials.gg
CompletedNCT00106626Updated Apr 22, 2009Results posted

Suberoylanilide Hydroxamic Acid in Advanced Solid Tumors

A Phase 1 interventional study of vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]) in combination with Pemetrexed and Cisplatin in Advanced Cancer, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-04-22.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
52
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies testing vorinostat in Carcinoma, Non-Small-Cell Lung — none open to participants now, 1 under way, none of them phase 3. Vorinostat · Carcinoma, Non-Small-Cell Lung.

Enrollment
5th of 19
52 · median 21
Started
2005
with 1 other
Phase 1
11 of 20
none open now
Registered
2nd of 20
by date
Lead sponsor
6 of 20
Merck Sharp & Dohme LLC

Among the 20 studies testing vorinostat in Carcinoma, Non-Small-Cell Lung, this one is the 5th largest by enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2005, is one of 11 in phase 1, and was the 2nd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

None of the 20 studies testing vorinostat in Carcinoma, Non-Small-Cell Lung is open now. The open studies under Carcinoma, Non-Small-Cell Lung, anywhere →

Where they have run

About vorinostat

Vorinostat: first FDA approval 2006 (ZOLINZA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 20 studies testing vorinostat in Carcinoma, Non-Small-Cell Lung as a file.
02

Study summary

The purpose of this investigational study is to determine the safety and tolerability of oral suberoylanilide hydroxamic acid when administered in combination with standard doses of pemetrexed and cisplatin for the treatment of advanced solid tumors.

03

Conditions studied

  • Advanced Cancer

Keywords

  • Advanced solid tumors including MPM and NSCLC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient must be 18 years or older with confirmed diagnosis of a solid tumor for which pemetrexed and cisplatin is acceptable treatment and have received no more than 2 prior systemic therapies
  • Has at least 1
  • Has adequate blood, liver, and kidney functions
  • Has not received any chemotherapy for at least 4 weeks prior to entry in this study
  • Agrees to take adequate measures to prevent pregnancy as outlined in the protocol

Exclusion criteria

Exclusion Criteria:

  • Patient has been treated with other agents with a similar anti-tumor mechanism
  • Patient from Cohorts A and B has received pemetrexed or cisplatin within the past 6 months and from Cohorts C and D have received pemetrexed within the past 6 months
  • Patient from Cohorts A and B has preexisting Grade 2 or higher neuropathy and from Cohorts C and D have Grade 3 or higher neuropathy
  • Patient has active infection or had received IV (intravenous) antibiotic, antiviral, or antifungal medications within 2 weeks of the start of study drugs
  • Patient has , or infection
  • Patient is pregnant or breast feeding
  • Patient has allergy to any component of the study drugs
  • Patient has history of GI (gastrointestinal) surgery or conditions
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    1

    vorinostat (Suberoylanilide Hydroxamic Acid \[SAHA\])

    Drug: vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]) in combination with Pemetrexed and Cisplatin

Interventions

  • Drugvorinostat (Suberoylanilide Hydroxamic Acid [SAHA]) in combination with Pemetrexed and Cisplatin

    Drug page: Vorinostat

    Dose escalation study starting with vorinostat (Suberoylanilide Hydroxamic Acid \[SAHA\]) capsules 200 mg b.i.d. in combination with Pemetrexed and Cisplatin (see table for Reporting Groups).

    Also known as: MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA)

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose (MTD) Status as Determined by Number of Participants With Dose Limiting Toxicity (DLT) at Each Dose Level

    MTD was determined by the occurrence of DLTs during the first treatment cycle. DLT describes side effects of a drug or other treatment that are serious enough to prevent an increase in dose or level of that treatment. The dose level is equal to the MTD if \< 2 patients experience a DLT and is also the highest tolerated dose level in the cohort.

    Time frame: Cycle 1 (21 days)

Secondary outcomes

  1. Safety and Tolerability as Measured by the Number of Participants With Disease Progression

    Number of participants with disease progression (protocol-mandated reason for discontinuation). Disease progression was determined by the principle investigator.

    Time frame: Any time during 8 cycle treatment period through 30 days after.

07

Results

Posted Apr 22, 2009

Participant flow

First Patient In = 29-Aug-05. Last Patient Last Visit = 03-Dec-07. Multicenter (4 Outpatient Clinics) in US.

Participant flow — Overall Study
MilestoneCohort A - Vorinostat BID + Pemetrexed + CisplatinCohort B - Vorinostat QD + Pemetrexed + CisplatinCohort C - Vorinostat BID + PemetrexedCohort D - Vorinostat QD + Pemetrexed
Started1391416
Completed3323
Not completed1061213
Withdrew: Adverse event5433
Withdrew: Progressive disease41910
Withdrew: Received radiation on new therapy1000
Withdrew: > 14 day delay in therapy start0100

Outcome measures

PrimaryMaximum Tolerated Dose (MTD) Status as Determined by Number of Participants With Dose Limiting Toxicity (DLT) at Each Dose Level

MTD was determined by the occurrence of DLTs during the first treatment cycle. DLT describes side effects of a drug or other treatment that are serious enough to prevent an increase in dose or level of that treatment. The dose level is equal to the MTD if \< 2 patients experience a DLT and is also the highest tolerated dose level in the cohort.

Time frame:
Cycle 1 (21 days)
Reported as:
Number · Participants
Maximum Tolerated Dose (MTD) Status as Determined by Number of Participants With Dose Limiting Toxicity (DLT) at Each Dose Level
ParticipantsDose Level A.1Dose Level A.2Dose Level B.1Dose Level B.2Dose Level C.1Dose Level C.2Dose Level C.3Dose Level D.1Dose Level D.2
Number (#) of DLT130210012
# Participants treated at a dose level <MTD000074000
# Participants treated at a dose level =MTD603000390
# Participants treated at a dose level >MTD070600007
SecondarySafety and Tolerability as Measured by the Number of Participants With Disease Progression

Number of participants with disease progression (protocol-mandated reason for discontinuation). Disease progression was determined by the principle investigator.

Time frame:
Any time during 8 cycle treatment period through 30 days after.
Reported as:
Number · Participants
Safety and Tolerability as Measured by the Number of Participants With Disease Progression
ParticipantsCohort A - Vorinostat BID + Pemetrexed + CisplatinCohort B - Vorinostat QD + Pemetrexed + CisplatinCohort C - Vorinostat BID + PemetrexedCohort D - Vorinostat QD + Pemetrexed
Safety and Tolerability as Measured by the Number of Participants With Disease Progression41910

Baseline characteristics

Age Continuous
Age Continuous(years)Cohort A - Vorinostat BID + Pemetrexed + CisplatinCohort B - Vorinostat QD + Pemetrexed + CisplatinCohort C - Vorinostat BID + PemetrexedCohort D - Vorinostat QD + PemetrexedTotal
Mean60.52 (35 to 81)58.23 (31 to 74)60.09 (41 to 78)63.63 (39 to 81)61 (31 to 81)
Sex: Female, Male
Sex: Female, Male(Participants)Cohort A - Vorinostat BID + Pemetrexed + CisplatinCohort B - Vorinostat QD + Pemetrexed + CisplatinCohort C - Vorinostat BID + PemetrexedCohort D - Vorinostat QD + PemetrexedTotal
Female457824
Male947828
Race/Ethnicity
Race/Ethnicity(participants)Cohort A - Vorinostat BID + Pemetrexed + CisplatinCohort B - Vorinostat QD + Pemetrexed + CisplatinCohort C - Vorinostat BID + PemetrexedCohort D - Vorinostat QD + PemetrexedTotal
Asian00011
Black02013
European01001
Hispanic American10023
White126141244
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2005, a primary completion of Dec 2007 and a completion of Dec 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2009, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2005
First posted
Mar 29, 2005
Start
Aug 2005
Primary completionActual
Dec 2007
CompletionActual
Dec 2007
Results first posted
Apr 22, 2009
Last update
Apr 22, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00106626
First posted
Mar 29, 2005
Start date
Aug 2005
Primary completion
Dec 2007
Completion
Dec 2007
Results posted
Apr 22, 2009
Last update
Apr 22, 2009

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vorinostat

Start the discussion